GW Pharmaceuticals plc, of London, said it priced an underwritten public offering and will issue 1.9 million American depositary shares (ADSs), representing 22.8 million ordinary shares, at $158 per ADS on Nasdaq. The transaction will raise gross proceeds of approximately $300 million, and the underwriters have been granted a 30-day option to purchase up to an additional 285,000 ADSs.